Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 2, 2013, Pages 277-282

  Miyaji, Karina Takesaki ^a,b   Luiz, Andre MacHado ^a,b   Lara, Amanda Nazareth ^a,b   Chaves, Tania Do Socorro Souza ^a,b   Piorelli, Roberta De Oliveira ^a,b   Lopes, Marta Heloisa ^a,b   Sartori, Ana Marli Christovam ^a,b  

^a Centro de Referencia Para Imunobiologicos Especiais (CRIE)   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Adverse events following immunization; Seniors; Yellow fever vaccine

Indexed keywords

ANALGESIC AGENT; ANTIPYRETIC AGENT; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; YELLOW FEVER VACCINE;

ADULT; AGED; ARTICLE; BRAZIL; CONTROLLED STUDY; DEMOGRAPHY; DRUG SAFETY; EDEMA; ERYTHEMA; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNIZATION; IMMUNOCOMPETENCE; INFECTION RISK; INJECTION SITE PAIN; INJECTION SITE REACTION; JAUNDICE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MYALGIA; OBSERVATIONAL STUDY; PAIN; PROSPECTIVE STUDY; TELECONSULTATION; VACCINATION; YELLOW FEVER; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; INCIDENCE; INTERVIEW; MIDDLE AGED; PATHOLOGY;

AGED; BRAZIL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INCIDENCE; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VACCINATION; YELLOW FEVER; YELLOW FEVER VACCINE;

EID: 84874701077     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.22714     Document Type: Article

References (20)

1. Camara FP, Gomes AL, Carvalho LM, Castello LG. Dynamic behavior of sylvatic yellow fever in Brazil (1954-2008). Rev Soc Bras Med Trop 2011; 44:297-9; PMID:21537794; http://dx.doi.org/10.1590/S0037-86822011005000024.
2. World Health Organization. Yellow fever vaccine. WHO position paper. Wkly Epidemiol Rec 2003
3. Monath T, Cetron M, Teuwen D. Yellow fever vaccine In: SA
4. Vasconcelos PF, Luna EJ, Galler R, Silva LJ, Coimbra TL, Barros VL, et al.; Brazilian Yellow Fever Vaccine Evaluation Group. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001; 358:91-7; PMID:11463409; http://dx.doi.org/10.1016/S0140-6736(01) 05326-0.
5. Ministerio da Saude /Secretaria de Vigilancia em Saude. Emergencias em Saude Publica de Importancia Nacional (ESPIN) de Febre Amarela Silvestre em Sao Paulo e no Rio Grande do Sul e a Situacao Epidemiologica Atual no Brasil (2008/2009). Febre Amarela Silvestre, Brasil, 2009.
6. Michael Marcy S, Kohl KS, Dagan R, Nalin D, Blum M, Jones MC, et al.; Brighton Collaboration Fever Working Group. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine 2004; 22:551-6; PMID:14741143; http://dx.doi.org/10.1016/ j.vaccine.2003.09.007. (Pubitemid 38114880)
7. Jones JF, Kohl KS, Ahmadipour N, Bleijenberg G, Buchwald D, Evengard B, et al.; Brighton Collaboration Fatigue Working Group. Fatigue: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007; 25:5685-96; PMID:17400340; http://dx.doi.org/10.1016/j. vaccine.2007.02.065. (Pubitemid 47043208)
8. Gidudu J, Sack DA, Pina M, Hudson MJ, Kohl KS, Bishop P, et al.; Brighton Collaboration Diarrhea Working Group. Diarrhea: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011; 29:1053-71; PMID:21130754; http://dx.doi.org/10.1016/j.vaccine. 2010.11.065.
9. Gidudu J, Kohl KS, Halperin S, Hammer SJ, Heath PT, Hennig R, et al.; Brighton Collaboration Local Reactions Working Group for a Local Reaction at or near Injection Site. A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2008; 26:6800-13; PMID:18950670; http://dx.doi.org/10.1016/ j.vaccine.2008.10.006.
10. Gidudu JF, Walco GA, Taddio A, Zempsky WT, Halperin SA, Calugar A, et al.; Brighton Immunization Site Pain Working Group. Immunization site pain: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2012; 30:4558-77; PMID:22521267; http://dx.doi.org/10.1016/j.vaccine.2012.03.085.
11. Camacho LA, de Aguiar SG, Freire MdaS, Leal MdaL, do Nascimento JP, Iguchi T, et al.; Collaborative Group for the Study of Yellow Fever Vaccines. Reactogenicity of yellow fever vaccines in a randomized, placebocontrolled trial. Rev Saude Publica 2005; 39:413-20; PMID:15997317; http://dx.doi.org/10. 1590/S0034-89102005000300012. (Pubitemid 41200551)
12. Monath TP, Cetron MS, McCarthy K, Nichols R, Archambault WT, Weld L, et al. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin 2005; 1:207-14; PMID:17012867; http://dx.doi.org/10.4161/hv.1.5.2221.
13. Martin M, Tsai TF, Cropp B, Chang GJ, Holmes DA, Tseng J, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001; 358:98-104; PMID:11463410; http://dx.doi.org/10.1016/S0140-6736(01)05327-2. (Pubitemid 32709847)
14. Monath TP. Suspected yellow fever vaccine-Associated viscerotropic adverse events (1973 and 1978), United States. Am J Trop Med Hyg 2010; 82:919-21; PMID:20439976; http://dx.doi.org/10.4269/ajtmh.2010.10-0001.
15. Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T. The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review. Am J Trop Med Hyg 2012; 86:359-72; PMID:22302874; http://dx.doi.org/10.4269/ajtmh.2012.11-0525.
16. Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, Marano N, et al. Adverse event reports following yellow fever vaccination. Vaccine 2008; 26:6077-82; PMID:18809449; http://dx.doi.org/10.1016/j.vaccine.2008.09.009.
17. Barrett AD, Teuwen DE. Yellow fever vaccine-how does it work and why do rare cases of serious adverse events take place? Curr Opin Immunol 2009 21 308-13 PMID:19520559 http://dx.doi.org/10.1016/j. coi.2009.05.018.
18. Menezes Martins RM, Santos EM, Cruz RLS, Santos PRS, Carvalho SMD, Sato HK, et al. Yellow fever vaccine post-marketing surveillance in Brazil. Procedia in Vaccinology. 2010
19. Durbin AP, Setse R, Omer SB, Palmer JG, Spaeder JA, Baker J, et al. Monitoring adverse events following yellow fever vaccination using an integrated telephone and Internet-based system. Vaccine 2009; 27:6143-7; PMID:19712766; http://dx.doi.org/10.1016/j.vaccine. 2009.08.024.
20. Roukens AH, Soonawala D, Joosten SA, de Visser AW, Jiang X, Dirksen K, et al. Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study. PLoS ONE 2011; 6:e27753; PMID:22163273; http://dx.doi.org/10.1371/journal. pone.0027753.